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Abstract
Background: Decision-makers have begun to recognize Health-Related Quality of Life (HRQoL) as an 
important and measurable outcome of healthcare interventions; and HRQoL data is increasingly being 
used by policy-makers to prioritize health resources. Our objective was to measure HRQoL in a group of 
Type 2 Diabetes Mellitus (T2DM) patients receiving insulin treatment in Buenos Aires, Argentina. 
Methods: We conducted a cross-sectional study of patients with T2DM over 21 years of age, treated 
with either Neutral Protamine Hagedorn (NPH) insulin or Insulin Glargine (IG), who had not changed 
their baseline schedule in the last 6 months. The recruitment was during 2006–7 in nine private diabetes 
specialists’ offices in Buenos Aires, Argentina. A standardized diabetes-specific HRQoL questionnaire, 
the Audit of Diabetes Dependent Quality of Life (ADDQoL), was used.
Results: A total of 183 patients were included (93 receiving NPH and 90 receiving IG). The mean QoL 
score was: 0.98 (SD: 0.89) and the diabetes specific QoL was: -1.49 (SD: 0.90). T2DM had a negative 
impact on HRQoL with a mean Average Weighted Impact (AWI) score on QoL of -1.77 (SD: 1.58). The 
greatest negative impact was observed for domains: ‘worries about the future’, ‘freedom to eat’, ‘living 
conditions’, ‘sex life’, and ‘family life’. The mean AWI score was -1.71 (SD: 1.48) in patients treated with IG 
and -1.85 (SD: 1.68) in patients receiving NPH, this difference was not statistically significant. 
Conclusion: The ADDQoL questionnaire is a tool that can be used in Argentina to measure the QoL 
of patients with diabetes when evaluating diabetes care programs. The scores of QoL in our selected 
population did not differ from those reported in high-income countries. We expect that the results of this 
study will increase healthcare providers’ awareness of patients’ perceived QoL and help to overcome the 
barriers that delay insulin treatment; mainly clinical inertia and patient resistance.
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Implications for policy makers
• The Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire is a tool that can be used in Argentina to measure the QoL of 
patients with diabetes when evaluating diabetes care programs.
• The assessment of patient-reported outcomes could be easily incorporated into ambulatory practice and can provide valuable information 
when evaluating diabetes care programs.
• While diabetes adversely affects QoL, patients treated with insulin in middle-income countries can maintain a high QoL similar to that 
observed in patients with diabetes in high-income countries.
• This can be a valuable argument to help overcome barriers that delay insulin treatment, like clinical inertia and patient resistance. 
Implications for public
Nowadays, it is unanimously recognized that Health-Related Quality of Life (HRQoL) is an important and measurable outcome of healthcare 
interventions. Increasingly, health professionals and policy-makers are using HRQoL data to make decisions about treatment options and 
prioritization of health resources. As expected, our study confirmed that diabetes negatively affects the QoL of patients in Argentina. However, 
while the impact on QoL was similar to that reported by studies in other parts of the world, our study patients, all treated with insulin, were able to 
maintain QoL levels comparable to those of patients in high-income countries. As insulin is one of the most effective measures to achieve diabetes control, 
this should be a good reason not to delay insulin treatment when indicated.
Key Messages 
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Background 
Traditionally, the impact of a chronic disease has been 
measured in terms of either morbidity or mortality. However, 
researchers have begun to recognize Health-Related Quality 
of Life (HRQoL) as an important and measurable outcome 
of healthcare interventions. In patients with diabetes, it may 
predict an individual’s capacity to manage this condition and 
to maintain long-term health and well-being (1). Importantly, 
HRQoL data is also used by policy-makers to make decisions, 
particularly in regards to resource allocation for diabetes and 
other chronic diseases (2,3).
Diabetes Mellitus (DM) negatively impacts HRQoL. This 
negative impact affects multiple aspects of a person’s life, 
including the psychological impact of being chronically 
ill, dietary restrictions, changes in social life, symptoms of 
inadequate metabolic control, chronic complications and 
ultimately lifelong disabilities (3–8). Many variables have been 
associated with HRQoL in patients with DM: age, gender, 
socio-economic status, obesity, type of DM, treatment, 
chronic complications, health insurance, quality of care and 
patient education (4,9–12).
In Argentina, high rates of physical inactivity, unhealthy diets 
and obesity have led to an increase in the prevalence of DM. 
The rates of DM increased from 8.4% in 2005 to 9.6% in 
2009 (13).
Several studies have shown unnecessary delays in the 
initiation of insulin therapy, especially in developing 
countries. Clinical inertia as well as patients’ concerns about 
the potential negative impact of insulin therapy on their 
QoL are the main barriers to the timely initiation of this 
treatment (14).
Despite its importance, there is no information about QoL 
in patients with Type 2 Diabetes Mellitus (T2DM) receiving 
insulin therapy in Argentina.
The primary objective of this study was to measure HRQoL 
in a group of  T2DM receiving insulin treatment in Buenos 
Aires, Argentina, through a standardized diabetes-specific 
HRQoL questionnaire, the Audit of Diabetes Dependent 
Quality of Life (ADDQoL). The secondary objective was to 
explore variables related to HRQoL in these patients.
Methods
We performed a cross-sectional study to describe HRQoL in a 
group of patients suffering from T2DM. A consecutive sample 
of eligible patients with T2DM, treated by diabetes specialists 
at private medical offices in Buenos Aires, Argentina, was 
taken for this study. We included patients with T2DM over 21 
years of age, treated with either Neutral Protamine Hagedorn 
(NPH) insulin or Insulin Glargine (IG), who had not changed 
their baseline schedule in the last 6 months. They were invited 
to participate during their usual doctor’s visit. We included 9 
private doctor’s offices. At the time of the recruitment, during 
2006–7, IG and NPH were the only insulin baseline treatment 
schemes available in Argentina. Although the proportion of 
patients receiving NPH in Argentina was greater than that 
of those receiving IG, the use of long-acting basal insulin 
analogues was growing rapidly in the country.
Pregnant and lactating women and patients with any 
unstable medical illness, mental disease, the inability to 
read or write and those who chose not to participate in the 
study were excluded. 
Assessment of Quality of Life (QoL)
We used the validated Spanish version for Argentina of the 
ADDQoL. The original version of the ADDQoL in English 
was translated and transculturally adapted to Argentina by 
Perrotta and Irazola (15) showing an adequate reliability and 
validity. The ADDQoL has been designed to allow users to 
rate the impact of diabetes on different domains, together 
with the perceived importance of each domain on their 
HRQoL (16). This instrument consists of 20 items dealing 
with 18 life domains. The individual items are formulated 
in the format of “If I did not have diabetes my [life domain] 
would be”: (very much better/much better/a little better/the 
same/worse/much worse/very much worse). Each item is 
scored on a 7-point scale (-3 maximum negative impact of 
diabetes to +3 maximum positive impact of diabetes). Then, 
the respondent indicates whether the item is very important, 
important, quite important, or not at all important for him or 
her (3 to 0). The respondent is allowed to indicate if an item is 
not applicable to his or her condition. Scoring and importance 
are multiplied for the applicable items and averaged to 
determine the final score (range -9 maximum negative impact 
of diabetes to +9 maximum positive impact of diabetes). An 
Average Weighted Impact (AWI) score is derived by adding 
the weighted impact scores for each domain and dividing 
by the number of applicable domains. The AWI score can 
range from –9 (maximum negative impact) to +9 (minimum 
negative impact).
Life domains included in the questionnaire were: Work life 
and work-related opportunities, family life, friendship and 
social life, sex life, physical appearance, physical health, 
holidays or leisure activities, local or long distance journeys, 
confidence to do things, motivation to achieve things, the way 
society reacts, worries about the future, financial situation, 
unwanted dependence on others, living conditions, freedom 
to eat, enjoyment of food, and freedom to drink [respondents 
may indicate Not Applicable (NA) as a response for work 
life and work-related opportunities, family life and sex life 
domains]. In addition to the assessment of these domains, the 
ADDQoL also includes two global measures. The first one 
evaluates the global Quality of Life (present QoL) “In general, 
my present QoL is”: (excellent/very good/good/neither good 
nor bad/bad/very bad/extremely bad) (range -3 to +3). The 
second evaluates the global impact of diabetes on QoL (QoL 
specific diabetes) in the format “If I did not have diabetes my 
QoL would be”: (very much better… very much worse) (range 
–3 to +3).
We collected socio-demographic data (gender, level of 
education, health coverage), diabetes complications and 
associated conditions (duration, presence of macrovascular 
and/or microvascular complications, other chronic conditions 
such as hypertension, hyperlipidemia or obesity), diabetes 
therapy and other medications for chronic conditions, 
diabetes education [according to QUALIDIAB criteria (17)], 
compliance with diet and physical exercise, clinical parameters 
(body weight, height) and laboratory measurements 
(glycaemia, glycosylated hemoglobin, cholesterol total, Low-
density and high-density lipoprotein, triglycerides, creatinine 
and microalbuminuria).
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Sample size
We estimated a sample size in order to obtain 95% Confidence 
Intervals (CI) of the QoL score with an error estimation of 
0.30 points (semi-amplitude). Based on previous studies 
(16,18,19), we anticipated a QoL mean score in T2DM patients 
of 1.20 ± 1.30 (mean ± SD). We included an additional 20% to 
the total sample to account for the possibility of loss of follow 
up or incomplete data based on experiences of previous field 
work conducted by our research group. The total sample 
size for our study based on these criteria required 90 T2DM 
patients treated with NPH insulin and 90 with IG.
 
Statistical analysis
Descriptive statistics were calculated for all variables 
measured. We used the Chi-Square test to explore the 
association between categorical variables. For continuous 
variables, we used the independent-sample T-Test or the 
Wilcoxon rank-sum test according to the distribution of the 
analysed variables. P-values of less than 0.05 (two-tailed) 
were considered to be statistically significant. We calculated 
the mean, standard deviation and median of the ADDQoL 
measures and performed subgroup analyses to examine the 
association of socio-demographic characteristics, level of 
glycemic control and diabetes complications with ADDQoL 
scores. Additionally, three robust regression models were 
built in order to adjust for potential confounders. Model 
selection was performed following a stepwise approach. 
Linearity was tested through augmented component-plus-
residual plots. Outliers and potential influence were explored 
by calculating studentized residuals and Cook’s distance for 
each observation. The reliability of the scale was determined 
by assessing the Cronbach alpha coefficient. Item missing rate 
was used to check feasibility. Data analyses were performed 
using Stata version 8.0 (Stata Corp, College Station, TX, USA).
Results 
Patient characteristics
A total of 206 patients were invited to participate. Twenty-
three (11%) did not give their consent to participate or were 
excluded because of incomplete data. A total of 183 patients 
met the inclusion criteria and provided complete data for the 
analysis (93 receiving NPH and 90 receiving IG). Data on 
respondent characteristics are presented in Table 1.
Quality of Life (QoL)
The scale showed a satisfactory feasibility since the item 
missing values were lower than 2%. Analyses of reliability 
showed a high internal consistency (Cronbach alpha: 0.89). 
The mean present QoL score was 0.98 (SD: 0.89), the diabetes 
specific QoL was -1.49 (SD: 0.90) and the mean AWI score on 
QoL -1.77 (SD: 1.58), indicating an overall negative impact of 
DM on QoL in T2DM patients treated with insulin. 
When we explored the association of socio-demographic 
characteristics, level of glycemic control and diabetes 
complications with ADDQoL scores (Table 2), we only found 
significant differences in the analysis by gender. In the crude 
analysis, Present QoL was significantly better in men than 
women [mean: 1.25 (SD: 0.77) vs. 0.72 (SD: 0.95) P< 0.01]. 
This difference remained significant in the adjusted analysis 
(partial beta coefficient= -0.48; 95% CI: -0.84 to -0.12; 
P<  0.01). There was no difference in the DM specific QoL 
and AWI score. 
The mean AWI score was -1.71 (SD: 1.48) in the group of 
patients treated with IG and -1.85 (SD: 1.68) in the group of 
patients receiving NPH. This difference was not statistically 
significant. Likewise, for the remaining variables analyzed, 
we did not find statistically significant differences in the 
ADDQoL scores either in the bivariate analysis or after 
adjusting for age, gender, education, employment status, 
health insurance, obesity, Glycosylated Hemoglobin (HA1c) 
and diabetes complications.
In our analysis of the impact of diabetes on QoL for different 
domains (Table 3 and Figure 1), the greatest negative impact of 
T2DM was observed for the domain ‘worries about the future’ 
with a mean AWI score -2.54 (SD: 3.63). The other domains 
where ADDQoL showed a greater effect on HRQoL were, 
‘freedom to eat as I wish’ -2.47 (SD: 2.49)’, ‘living conditions’ 
-2.33 (SD: 2.63), ‘sex life’ -2.27 (SD: 2.60), and ‘family life’ -2.05 
(SD: 2.46).
The domains ‘sex life’ and ‘enjoyment of food’ were more 
affected in men than in women with a mean -2.96 (SD: 2.51) 
vs. -1.38 (SD: 2.49) P< 0.01; and -1.98 (SD: 2.33) vs. -1.21 (SD: 
2.45) P= 0.03, respectively. Alternatively, the domains ‘living 
conditions’ and ‘friendship and social life’ were more affected 
in women than in men with a mean -2.82 (SD: 2.55) vs. -1.89 
(SD: 2.67) P< 0.01; and -1.49 (SD: 2.14) vs. -0.98 (SD: 2.08) P= 
Table 1. Patient characteristics (n= 183)
Variables
Female, n (%) 88 (48.09)
Age (years), median (interquartile range) 65 (55-73)
Employed, n (%) 86 (46.99)
Health insurance, n (%) 180 (98.36)
≥12 years of formal education, n (%) 104 (56.83)
Adequate Diabetes educationa, n (%) 176 (96.17)
Duration of diabetes in years, mean ± SD 12.74 ± 8.30
HbA1c  (%),  mean ± SD 7.59 ± 1.97
HbA1c ≥8%b, n (%) 59 (32.24)
Bolus treatment with regular insulin, n (%) 139 (75.96)
Basal treatment
NPH insulin, n (%) 93 (50.82)
IG, n (%) 90 (49.18)
Number of daily insulin injections, mean ± SD 3.64 ± 1.61
Oral hypoglycemic agents, n (%) 82 (44.81)
Macroangiopathic complications, n (%) 51 (27.87)
Microangiopathic complications, n (%) 49 (26.78)
Acute complications
Diabetes-related hospitalizations, n (%) 6 (3.28)
Severe hypoglycemia, n (%) 7 (3.83)
Ketoacidosis, n (%) 1 (0.54)
Hyperosmolar syndrome, n (%) 0 (0.00)
Hypertension, n (%) 124 (67.76)
Hypercholesterolemia, n (%) 97 (53.00)
Current smokers, n (%) 25 (13.66)
BMI ≥ 30, n (%) 71 (38.80)
BMI= Body Mass Index; HbA1C= Glycosylated Hemoglobin; IG= Insulin 
Glargine.
a According to QUALIDIAB criteria (17).
b HbA1C ≥8% was defined as poor control.
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0.03, respectively. People younger than 65 years old showed a 
lower score than the elderly in the domain ‘worries about the 
future’ [mean: -3.16 (SD: 3.69) vs. -1.98 (SD: 3.55); P= 0.01].
Discussion 
This is the first study describing HRQoL in T2DM patients 
treated with insulin using a diabetes specific instrument as 
ADDQoL in Argentina. Our results showed that T2DM has a 
negative impact on HRQoL in a group of Argentinean diabetes 
patients treated with insulin. However, mean AWI scored 
were not significantly different between patient treated with 
NPH or IG. As stated by Polonsky, the relationship between 
HRQoL and diabetes is bidirectional; aspects of diabetes may 
negatively impact on HRQoL, and impaired HRQoL may 
also negatively influence diabetes self-management and thus 
health outcomes (20). Therefore, it is relevant to explore and 
understand those factors implicated in this relationship to 
Table 2. ADDQoL scores according to patient characteristics
Variables ADDQoL scores (Mean ± SD) P-valuea
Gender Male Female
Present QoL 1.25 ± 0.77 0.72 ± 0.95 <0.01
DM specific QoL -1.49 ± 1.25 -1.23 ± 1.11 0.50
AWI -1.76 ± 1.69 -1.79 ± 1.46 0.28
Age ≥65 years <65 years
Present QoL 0.98 ± 0.93 0.98 ± 0.86 0.73
DM specific QoL -1.50 ± 0.91 -1.49 ± 0.90 0.64
AWI -1.85 ± 1.79 -1.72 ± 1.34 0.23
BMI ≥30 Yes No
Present QoL 1.41 ± 1.43 1.34 ± 0.98 0.70
DM specific QoL -1.49 ± 0.88 -1.50 ± 0.93 0.76
AWI -1.66 ± 1.41 -1.84 ± 1.69 0.52
Basal treatment Glargine NPH
Present QoL 1.03 ± 0.94 0.94 ± 0.86 0.87
DM specific QoL -1.45 ± 0.98 -1.54 ± 0.83 0.97
AWI -1.71 ± 1.48 -1.85 ± 1.68 0.87
HbA1C (%) ≥8 <8
Present QoL 1.25 ± 1.21 1.54 ± 1.12 0.13
DM specific QoL -1.49 ± 0.87 -1.48 ± 0.92 0.52
AWI -1.71 ± 1.52 -1.80 ± 1.62 0.33
Diabetes complications  Yes No
Present QoL 1.36 ± 1.12 1.35 ± 1.21 0.97
DM specific QoL -1.52 ± 0.92 -1.47 ± 0.89 0.53
AWI -1.87 ± 1.55 -1.70 ± 1.61 0.34
≥12 years of formal 
education
Yes No
Present QoL 1.08 ± 0.91 0.82 ± 0.86 0.83
DM specific QoL -1.47 ± 0.86 -1.53 ± 0.85 0.69
AWI -1.60 ± 1.43 -2.02 ± 1.74 0.80
Employed Yes No
Present QoL 1.07 ± 0.77 0.87 ± 1.03 0.30
DM specific QoL -1.53 ± 0.97 -1.49 ± 0.95 0.49
AWI -1.54 ± 1.14 -2.00 ± 1.92 0.76
ADDQoL= Audit of Diabetes Dependent Quality of Life; QoL= Quality of 
Life; DM= Diabetes Mellitus; AWI: Average Weighted Impact; NPH= Neutral 
Protamine Hagedorn; BMI= Body Mass Index; HbA1C= Glycosylated 
Haemoglobin.
a P-values correspond to the multivariate analysis.
Table 3. Weighted impact scores for QoL domains in T2DM  patients
Life domain Mean SD Median
Worries about the future -2.54 3.63 -2
Freedom to eat as I wish -2.47 2.49 -2
Living conditions -2.33 2.63 -2
Sex life -2.27 2.60 -2
Family life -2.05 2.46 -2
The things I could do physically -1.98 2.44 -2
Ease of traveling (local or long distance) -1.88 2.40 -1
Holidays or leisure activities -1.85 2.40 -1
Work life and work-related opportunities -1.83 2.55 0
Motivation to achieve things -1.76 2.46 -1
Confidence in my ability to do things -1.71 2.17 -2
Enjoyment of food -1.64 2.46 -1
Physical appearance -1.48 2.37 -1
Finances -1.42 2.16 0
Unwanted dependence on others -1.24 2.85 0
Friendship and social life -1.23 2.12 0
Freedom to drink as I wish -1.11 2.15 0
The way society reacts to me -0.87 2.03 0
QoL= Quality of Life; T2DM= Type 2 Diabetes Mellitus.
Figure 1. Impact of diabetes on individual life domains.
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improve T2DM outcomes.
Some studies found that better glycemic control was 
associated with better HRQoL and that complications were 
the most important disease-specific determinant of HRQoL 
(4,21,22). However, other authors found no significant 
relationship between HRQoL and glycemic control (23–
25). In our study, glycemic control was not associated with 
HRQoL while patients with complications showed lower 
QoL scores than patients without complications, though 
this difference was not statistically significant. Additionally, 
men with T2DM reported higher scores in present QoL than 
women, a finding consistent with other studies in similar 
populations (9,12,26–29). 
Several studies showed that the most negatively impacted 
domains were those related to food, namely, ‘freedom to eat’, 
‘enjoyment of food’ and ‘freedom to drink’. Additionally, as 
found in our sample, ‘worries about the future’ is also one 
of the most affected domains (10,16,30–32). As expected, 
the negative impact of diabetes varies depending on the 
characteristics of the patients. For example, the domain 
‘worries about the future’ had particularly large negative 
impact on HRQoL, in the subgroup of subjects younger than 
65 years old. Collins et al. (30) showed that older age (60 years 
of age) might be associated with higher diabetes-related QoL 
scores, although this statistically significant association was 
diminished after adjusting for relevant factors. Sundaram 
et al. (33) also reported that older age (60 years of age) was 
independently associated with higher ADDQoL scores in a 
multivariate analysis. Differences between genders were also 
seen in domains such as sex life, friendship and social life and 
enjoyment of food, which is consistent with findings in other 
studies (9,26).
Our main limitation is that the study sample was drawn from 
specialized diabetes clinics rather than randomly selected 
centers, affecting the generalizability of our findings. Patients 
treated in specialist clinics usually have high health coverage 
and higher levels of diabetes education than those T2DM 
patients treated in public hospitals with no health coverage. 
On the other hand, the relatively small sample size did not 
allow us to further explore the potential association of QoL 
with socio-demographic characteristics and different aspects 
of the disease.
Conclusion
The ADDQoL questionnaire is a tool that can be used in 
Argentina to measure the QoL of patients with diabetes when 
evaluating diabetes care programs. The scores of QoL in our 
selected T2DM patient population did not differ from those 
reported in studies that included patients from high-income 
countries where there is access to a high level of diabetes care. 
While diabetes adversely affects QoL, patients treated with 
insulin in middle-income countries can maintain a high QoL 
similar to that observed in patients with diabetes in high-
income countries. In future studies, it would be advisable 
to implement this questionnaire in a different patient 
population, including lower educated patients with no health 
coverage treated in public health centers and T2DM patients 
exclusively on oral antidiabetic drugs. We strongly feel that the 
assessment of patient-reported outcomes should be extended 
and incorporated into ambulatory practice and taken into 
account in the evaluation of diabetes care programs.
Even though Argentina has a National Diabetes Program (34) 
which supplies free insulin for all diabetes patients, clinical 
inertia and patient resistance are still barriers that delay 
insulin treatment. We expect that the results of this study will 
increase healthcare providers’ awareness of patients’ perceived 
QoL and help to overcome these barriers.
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